Multitarget-Directed Antioxidants as Therapeutic Agents
Design of Hybrid Molecules for Drug Development, Page: 5-46
2017
- 8Citations
- 25Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Melatonin is a neurohormone produced in the pineal gland that regulates circadian rhythmicity, with maximal secretion at night. The natural decline of melatonin levels with age strongly contributes to the development of neurodegenerative disorders. Currently, melatonin is recognized as a powerful antioxidant compound, able to efficiently scavenge different types of ROS in vitro, in body fluids, and in cells. Thus it is not surprising that a number of modified melatonin derivatives have been designed, synthesized, and biologically assessed, resulting in new multitarget-directed ligands (MTDL). In this chapter we identify the melatonin hybrids resulting from the juxtaposition of tacrine, berberine, tamoxifen, curcumin, N, N- dibenzyl( N -methyl)amine, cinnamic acid, sulforaphane, pinoline, or meptazinol with melatonin. We discuss their pharmacological properties and highlighting in particular their antioxidant capacity as potential therapeutic agents for diverse pathologies. Other antioxidant agents such as ferulic acid as a source for new MTDL are also discussed.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780081010112000027; http://dx.doi.org/10.1016/b978-0-08-101011-2.00002-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85040611264&origin=inward; http://linkinghub.elsevier.com/retrieve/pii/B9780081010112000027; http://api.elsevier.com/content/article/PII:B9780081010112000027?httpAccept=text/plain; http://api.elsevier.com/content/article/PII:B9780081010112000027?httpAccept=text/xml; https://linkinghub.elsevier.com/retrieve/pii/B9780081010112000027; https://dx.doi.org/10.1016/b978-0-08-101011-2.00002-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know